Jill Beraud - May 4, 2022 Form 4/A - Amendment Insider Report for Revance Therapeutics, Inc. (RVNC)

Role
Director
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Stock symbol
RVNC
Transactions as of
May 4, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
5/13/2022, 06:08 PM
Date Of Original Report
May 6, 2022
Previous filing
Apr 22, 2022
Next filing
May 25, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVNC Stock Option (Right to buy) Award $0 +10.8K $0.00 10.8K May 4, 2022 Common Stock 10.8K $18.12 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Ms. Beraud's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) through such vesting date. The stock option represents an annual grant pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy.

Remarks:

The original Form 4, filed on May 6, 2022, inadvertently listed the incorrect number of options granted to the Reporting Person on May 4, 2022 due to an administrative error. This Form 4/A is being filed to correct the number of shares underlying the stock option originally reported.